Innovent Biologics Inc (1801): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 93,55 Hongkong Dollar | 112,7 Hongkong Dollar | 69,55 Hongkong Dollar |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 128,919 Hongkong Dollar | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 1.743.864.650 | - | - |
Kennzahl in 1000 CNY | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | 13.041.523 | 9.421.888 | 6.206.070 | 4.556.380 | 4.269.729 | 3.843.819 | 1.047.525 | 9.477 | 18.538 | 32.127,154 |
Cashflow aus operativer Geschäftstätigkeit | 10.001.012 | 1.287.024 | 147.810 | -1.918.804 | -2.024.843 | -307.688 | -1.664.473 | -1.016.019 | -492.270 | -362.993 |
▸ Operative Cashflow Marge | 76,69% | 13,66% | 2,38% | -42,11% | -47,42% | -8% | -158,9% | -10.720,89% | -2.655,46% | -1.129,86% |
Investitionsausgaben (CapEx) | 683.274 | 1.705.412 | 1.383.460 | 1.381.730 | 1.847.516 | 771.778 | 365.873 | 312.739 | 90.971 | 58.444 |
Cashflow aus Investitionstätigkeit | -6.511.540 | -1.165.411 | -998.662 | -1.435.185 | -2.698.148 | -5.184.588 | -2.569.157 | 859.417 | -349.456 | -572.079 |
Cashflow aus Finanzierungstätigkeit | 4.728.470 | -606.632 | 2.587.257 | 2.892.082 | 5.003.361 | 4.912.121 | 2.109.315 | 4.433.863 | 89.406 | 1.639.605 |
Freier Cashflow | 9.317.738 | -418.388 | -1.235.650 | -3.300.534 | -3.872.359 | -1.079.466 | -2.030.346 | -1.328.758 | -583.241 | -421.437 |
▸ Freie Cashflow Marge | 71,45% | -4,44% | -19,91% | -72,44% | -90,69% | -28,08% | -193,82% | -14.020,87% | -3.146,19% | -1.311,78% |
Ausgeschüttete Dividenden | - | - | - | - | - | - | - | - | - | - |
Neuausgabe und Rückkäufe von Stammaktien | - | 84.312 | 2.255.116 | 2.131.059 | 3.950.520 | 4.662.363 | 2.174.808 | 3.371.363 | 104.247 | -1 |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.